Stock Events

Orexo AB 

€1.8
0
+€0+0% Today

Statistics

Day High
1.8
Day Low
1.8
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
56.91M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

2NovConfirmed
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-2.15
-1.5
-0.85
-0.2
Expected EPS
-1.68
Actual EPS
-0.77

People Also Follow

This list is based on the watchlists of people on Stock Events who follow C5G.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Show more...
CEO
Mr. Nikolaj Sorensen
Employees
116
Country
SE
ISIN
SE0000736415
WKN
000A0HG6G

Listings